aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.
Company profile
Ticker
AYTU
Exchange
Website
CEO
Joshua R. Disbrow
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AYTU BIOSCIENCE, INC, Rosewind CORP
SEC CIK
Corporate docs
Subsidiaries
Aytu Therapeutics, LLC • Innovus Pharmaceuticals, Inc. • Semprae Laboratories, Inc • Supplement Hunt, Inc. • Delta Prime Savings Club, Inc • Neos Therapeutics, Inc. • Neos Therapeutics Brands, LLC • Neos Therapeutics, LP • PharmaFab Texas, LLC ...
AYTU stock data
Latest filings (excl ownership)
8-K
Aytu BioPharma Reports Record ADHD Revenue and Operating
14 Feb 24
10-Q
2024 Q2
Quarterly report
14 Feb 24
8-K
Entry into a Material Definitive Agreement
17 Nov 23
8-K
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
14 Nov 23
10-Q
2024 Q1
Quarterly report
14 Nov 23
8-K
Aytu BioPharma Announces Approval of the Cotempla XR-ODT® Manufacturing Site Transfer Prior Approval Supplement
26 Oct 23
10-K
2023 FY
Annual report
12 Oct 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
NT 10-K
Notice of late annual filing
29 Sep 23
8-K
Results of Operations and Financial Condition
27 Sep 23
Transcripts
AYTU
Earnings call transcript
2024 Q2
14 Feb 24
AYTU
Earnings call transcript
2024 Q1
14 Nov 23
AYTU
Earnings call transcript
2023 Q4
27 Sep 23
AYTU
Earnings call transcript
2023 Q3
11 May 23
AYTU
Earnings call transcript
2023 Q2
21 Feb 23
AYTU
Earnings call transcript
2023 Q1
14 Nov 22
AYTU
Earnings call transcript
2022 Q4
28 Sep 22
AYTU
Earnings call transcript
2022 Q1
16 Nov 21
AYTU
Earnings call transcript
2021 Q4
27 Sep 21
AYTU
Earnings call transcript
2021 Q3
18 May 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.96 mm | 19.96 mm | 19.96 mm | 19.96 mm | 19.96 mm | 19.96 mm |
Cash burn (monthly) | 1.01 mm | 320.58 k | 2.71 mm | 2.16 mm | 70.33 k | (no burn) |
Cash used (since last report) | 6.90 mm | 2.20 mm | 18.55 mm | 14.81 mm | 482.15 k | n/a |
Cash remaining | 13.06 mm | 17.77 mm | 1.41 mm | 5.15 mm | 19.48 mm | n/a |
Runway (months of cash) | 13.0 | 55.4 | 0.5 | 2.4 | 277.0 | n/a |
Institutional ownership, Q2 2023
89.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 9 |
Closed positions | 2 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 2.60 bn |
Total shares | 5.01 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 3.28 mm | $0.00 |
Nantahala Capital Management | 1.09 mm | $1.74 bn |
Stonepine Capital Management | 472.37 k | $755.79 mm |
Renaissance Technologies | 57.32 k | $92.00 k |
BLK Blackrock | 24.06 k | $38.50 mm |
Integrated Core Strategies | 22.87 k | $226.00 k |
Acadian Asset Management | 22.54 k | $35.00 k |
PRU Prudential Financial | 19.58 k | $31.32 mm |
Geode Capital Management | 11.90 k | $19.03 mm |
Tower Research Capital | 7.17 k | $11.48 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Greg Pyszczymuka | Common Shares | Option exercise | Acquire M | No | No | 0 | 208 | 0.00 | 22,768 |
31 Mar 24 | Greg Pyszczymuka | RSU Common Shares | Option exercise | Dispose M | No | No | 0 | 208 | 0.00 | 834 |
31 Dec 23 | Greg Pyszczymuka | Common Shares | Option exercise | Acquire M | No | No | 0 | 209 | 0.00 | 22,560 |
31 Dec 23 | Greg Pyszczymuka | RSU Common Shares | Option exercise | Dispose M | No | No | 0 | 209 | 0.00 | 1,042 |
30 Sep 23 | Greg Pyszczymuka | Common Shares | Option exercise | Acquire M | No | No | 0 | 208 | 0.00 | 22,351 |
30 Sep 23 | Greg Pyszczymuka | RSU Common Shares | Option exercise | Dispose M | No | No | 0 | 208 | 0.00 | 1,251 |
16 Aug 23 | Abhinav Jain | Common Shares | Grant | Acquire A | No | No | 0 | 6,500 | 0.00 | 8,000 |
11 Aug 23 | Greg Pyszczymuka | Employee Stock Option Common Shares | Grant | Acquire A | No | No | 1.73 | 7,000 | 12.11 k | 7,000 |
Press releases
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
3 Apr 24
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
2 Apr 24
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
14 Feb 24
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
7 Feb 24